Summary Alcobra Ltd (Alcobra) is a pharmaceutical company that develops and commercializes proprietary pharmaceutical products and novel treatments for CNS. The company offers non-stimulant products that are used in treatment of central nervous system disorders and cognitive dysfunctions. It provides development and commercialization of its investigational new novel Phase III drug candidate, metadoxine extended release. Alcbra’s MDX acts as a monoamine-independent modulator of GABA transmission. The company conducts clinical studies and separate Phase IIb trials of MDX. It also provides phase II studies and a phase III study of MDX in adults with ADHD. Alcobra is headquartered in Tel Aviv, Israel. Alcobra Ltd (ADHD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile. provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized... Research Beam Model: Research Beam Product ID: 1747393 250 USD New
Alcobra Ltd (ADHD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile.
 
 

Alcobra Ltd (ADHD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile.

  • Category : Pharmaceuticals
  • Published On : July   2017
  • Pages : 31
  • Publisher : GlobalData
 
 
 
Summary

Alcobra Ltd (Alcobra) is a pharmaceutical company that develops and commercializes proprietary pharmaceutical products and novel treatments for CNS. The company offers non-stimulant products that are used in treatment of central nervous system disorders and cognitive dysfunctions. It provides development and commercialization of its investigational new novel Phase III drug candidate, metadoxine extended release. Alcbra’s MDX acts as a monoamine-independent modulator of GABA transmission. The company conducts clinical studies and separate Phase IIb trials of MDX. It also provides phase II studies and a phase III study of MDX in adults with ADHD. Alcobra is headquartered in Tel Aviv, Israel.

Alcobra Ltd (ADHD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile. provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Alcobra Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Alcobra Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Alcobra Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Alcobra Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Alcobra Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Alcobra Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Teva Pharma Industries Enters Into Co-Development Agreement With Alcobra 10
Equity Offering 10
Alcobra Prices Public Offering of Shares for USD40 Million 10
Alcobra Raises USD29.9 Million in Public Offering of Shares 12
Alcobra Completes Public Offering Of Shares For US$38 Million 13
Alcobra Completes IPO For US$25 Million 14
Acquisition 16
Regenera Pharma May Acquire 66.6% Stake in Alcobra Pharma 16
Alcobra Ltd - Key Competitors 18
Key Employees 19
Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Recent Developments 21
Strategy And Business Planning 21
Jun 23, 2017: Alcobra Updates On Its Review Of Strategic Alternatives 21
Financial Announcements 22
May 30, 2017: Alcobra Announces First Quarter 2017 Financial Results and Provides Corporate Update 22
Feb 15, 2017: Alcobra Announces Fourth-Quarter and Full-Year 2016 Financial Results and Provides Corporate Update 23
Nov 15, 2016: Alcobra Announces Third Quarter 2016 Financial Results and Provides Corporate Update 24
Aug 30, 2016: Alcobra Announces Second Quarter 2016 Financial Results and Provides Corporate Update 25
May 16, 2016: Alcobra Announces First Quarter 2016 Financial Results and Provides Corporate Update 26
Feb 17, 2016: Alcobra Announces Fourth Quarter And Fiscal 2015 Financial Results And Provides Corporate Update 27
Corporate Communications 28
May 15, 2017: Alcobra Announces Leadership Update 28
Product Approvals 29
Feb 06, 2017: Alcobra Reports on Productive FDA Meeting for New Lead Product Candidate for ADHD 29
Jul 19, 2016: Alcobra Granted European Orphan Drug Designation for Metadoxine in Fragile X Syndrome 30
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31

List of Tables
Alcobra Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 1
Alcobra Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Alcobra Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Alcobra Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Alcobra Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Alcobra Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Teva Pharma Industries Enters Into Co-Development Agreement With Alcobra 10
Alcobra Prices Public Offering of Shares for USD40 Million 10
Alcobra Raises USD29.9 Million in Public Offering of Shares 12
Alcobra Completes Public Offering Of Shares For US$38 Million 13
Alcobra Completes IPO For US$25 Million 14
Regenera Pharma May Acquire 66.6% Stake in Alcobra Pharma 16
Alcobra Ltd, Key Competitors 18
Alcobra Ltd, Key Employees 19
Alcobra Ltd, Subsidiaries 20
List of Figures
Alcobra Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Alcobra Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Alcobra Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Alcobra Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Alcobra Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Alcobra Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6
Alcobra Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Alcobra Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
PURCHASE OPTIONS
 
 
 

How can we help you?

Contact us at the Consulting WP office nearest to you or submit a business inquiry online.


  Contact
 

Subscribe to Our Newsletter